ProTom International Inc., a developer of a proton therapy device to treat cancer, filed a Chapter 11 petition in Dallas on May 12 to sell the business (In re ProTom International Inc., Bankr. N.D. Tex., 15-32065, petition filed 5/12/15).
Flower Mound, Texas-based ProTom said it holds the exclusive U.S. rights to patented technology incorporated into its Radiance 330 system.
ProTom began actively marketing the system to potential buyers in mid-2009, leading to three sale contracts. In March 2014, the company received clearance from the U.S. Food and Drug Administration.
The first agreement for the sale and installation ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.